Allylix

About Allylix

Founded in 2002, Allylix, Inc. operated as a biotechnology company specializing in the production of terpenes through a proprietary yeast fermentation process. The company's creation stemmed from a collaboration that began in 1994 between plant pathologist Joe Chappell and biologist Joseph Noel, who discovered that their insights into plant enzymes could be applied to produce flavors and fragrances more economically. Carolyn Fritz, with a background in industrial biotechnology at Cargill and Dow Chemical, was appointed CEO in 2005 to lead the company. Allylix established its headquarters in San Diego, California, with research and development facilities in Lexington, Kentucky.

The company's core business centered on a technology platform that used metabolically engineered baker's yeast to convert sugars into high-value terpenes, which are natural compounds typically found in minute quantities in plants. This fermentation-based approach provided a stable and cost-effective alternative to traditional extraction from botanical sources, which is often subject to supply volatility and high costs. For instance, the company could produce valencene (an orange flavor) and nootkatone (a grapefruit flavor) for a fraction of the traditional extraction cost. Allylix's business model focused on supplying these ingredients to clients in the flavor and fragrance, food and beverage, and personal care industries. The technology also held potential for producing compounds for pharmaceutical, agricultural, and biofuel markets.

Allylix's primary products included Nootkatone, a citrus aroma found in grapefruit, and Valencene, an orange flavor and fragrance. These ingredients were targeted at flavor and fragrance manufacturers and large consumer product companies. Nootkatone also showed promise as an effective insect repellent against pests like ticks and mosquitoes. The company successfully scaled its manufacturing to industrial levels, capable of producing in 200,000-liter fermentation tanks. This capability allowed Allylix to offer a consistent, high-quality supply of terpenes that were previously difficult to source reliably. In a significant milestone, Allylix was acquired by the Swiss company Evolva Holding SA in a deal that closed in December 2014, making it a wholly owned subsidiary. The acquisition expanded Evolva's intellectual property portfolio, adding Allylix's 160 patents and applications to its own.